In search of negative allosteric modulators of biological targets

Drug Discovery Today

Volumn 14, Issue 1-2, 2009, Pages 41-49

  Groebe, Duncan R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYLAMINOPYRIMIDINE DERIVATIVE; 4 AMINOBUTYRIC ACID A RECEPTOR; ABELSON KINASE; ACETYLCHOLINE; ADENYLATE CYCLASE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR; BETA CARBOLINE; BUNGAROTOXIN RECEPTOR; CALCIUM CHANNEL L TYPE; CHEMOKINE RECEPTOR CXCR1; DIHYDROPYRIDINE; DILTIAZEM; FOLLITROPIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GONADORELIN ANTAGONIST; IMATINIB; INORGANIC PYROPHOSPHATASE; INTEGRIN; ISOXAZOLOPYRIDONE DERIVATIVE; METABOTROPIC RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; PYRIMIDINE DERIVATIVE; SADOPINE; STRYCHNINE; UNCLASSIFIED DRUG;

ALLOSTERISM; BEHAVIOR; BINDING COMPETITION; DOSE RESPONSE; DRUG BINDING SITE; DRUG MECHANISM; DRUG TARGETING; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE COMPLEX; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; NEUROCHEMISTRY; NEUROPHYSIOLOGY; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; REVIEW;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 58149136261     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.09.011     Document Type: Review

References (26)

1. Schindler T., et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289 (2000) 1938-1942
2. Shimaoka M., and Springer T.A. Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug. Discov. 2 (2003) 703-716
3. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug. Discov. 1 (2002) 198-210
4. Groebe D.R. Screening for positive allosteric modulators of biological targets. Drug Discov. Today 11 (2006) 632-639
5. Yanofsky S.D., et al. Allosteric activation of the follicle-stimulating hormone (FSH) receptor by selective, non-peptide agonists. J. Biol. Chem. 281 (2006) 13226-13233
6. Keating S.M., et al. Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the αl subunit of lymphocyte function-associated antigen-1. Protein Sci. 15 (2006) 290-303
7. Lazareno S., and Birdsall N.J.M. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligand at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48 (1995) 362-378
8. Lai C.-J., and Wu J.C. A simple kinetic method for rapid mechanistic analysis of reversible enzyme inhibitors assay. Drug Dev. Technol. 1 (2003) 527-535
9. Annis D.A., et al. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. J. Am. Chem. Soc. 126 (2004) 15495-15503
10. Christopoulos A., and Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54 (2002) 323-374
11. Litschig S., et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 55 (1999) 453-461
12. 2+ channel probe: characterization of two equipotent diastereomers with opposite allosteric properties. Mol. Pharmacol. 41 (1992) 298-30713
13. Ng H.J., et al. Nootropic α7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 8059-8064
14. Buchdunger E., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56 (1996) 100-104
15. Monod J., et al. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12 (1965) 88-118
16. Minton A.P., and Imai K. The three-state model: a minimal allosteric description of homotropic and heterotropic effect in the binding of ligands to hemoglobin. Proc. Natl. Acad. Sci. U. S. A. 71 (1974) 1418-1421
17. Segel I.H. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (1993), John Wiley & Sons
18. Fabrichniy I.P., et al. Structural studies of metal ions in family II pyrophosphatases: the requirement for a Janus ion. Biochemistry 43 (2004) 14403-14411
19. Delean A., et al. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled b-adrenergic receptor. J. Biol. Chem. 255 (1980) 7108-7117
20. Sullivan S.K., et al. Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists. Biochemistry 45 (2006) 15327-15337
21. Weiss J.M., et al. The cubic ternary complex receptor-occupancy model I. Model description. J. Theor. Biol. 178 (1996) 151-167
22. Bertini, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11791-11796
23. Hall D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58 (2000) 1412-1423
24. Suzuki G., et al. In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists. J. Pharmacol. Exp. Ther. 323 (2007) 147-156
25. Evans A.K., and Lowry C.A. Pharmacology of the beta-carboline FG-7,142, a partial inverse agonist at the benzodiazepine allosteric site of the GABA A receptor: neurochemical, neurophysiological, and behavioral effects. CNS Drug Rev. 13 (2007) 475-501
26. Campo-Soria C., et al. Mechanism of action of benzodiazepines on GABAA receptors. Br. J. Pharmacol. 148 (2006) 984-990